Dexmedetomidine constant-rate infusion suppresses insulin secretion and impairs glucose tolerance in healthy dogs

Read full text Summarise with VIRAT
Authors: Kenichi Maeda, Misaki Inada, Satomi Iwai, Shozo Okano
Cited by: 0
References: 23

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Objective: To evaluate the effects of dexmedetomidine (DEX) constant-rate infusion (CRI) on glucose tolerance and metabolic responses in healthy dogs. Methods: In a prospective, randomized, repeated-measures study, 5 healthy adult Beagles received 4 treatments: low-dose DEX (1 µg/kg loading; 1 µg/kg/h CRI), medium-dose DEX (5 µg/kg loading; 5 µg/kg/h CRI), high-dose DEX (10 µg/kg loading; 10 µg/kg/h CRI), or saline. An IV glucose tolerance test was performed 30 minutes after CRI initiation. Serum glucose and insulin were measured. Data were analyzed using linear mixed-effects models, with treatment, time, and their interaction as fixed effects and dog as a random effect. Results are reported as effect sizes with 95% CIs. Results: DEX CRI suppressed insulin secretion in a dose-related manner during the early phase of the glucose tolerance test. Compared with control, glucose disappearance rate was reduced at medium (mean difference, -1.37%/min; 95% CI, -2.32 to -0.42) and high (mean difference, -1.45%/min; 95% CI, -2.36 to -0.54) infusion rates, whereas the low-dose treatment did not differ meaningfully (mean difference, -0.68%/min; 95% CI, -1.63 to 0.27). No clinically relevant adverse events occurred. Conclusions: DEX CRI causes dose-related suppression of insulin secretion and impairs glucose tolerance at medium and high infusion rates in healthy dogs. In contrast, the clinically used low infusion rate did not substantially alter glucose tolerance under study conditions. Clinical Relevance: Medium- and high-dose DEX CRI may impair glucose tolerance in healthy dogs, whereas the clinically used low-dose regimen appears unlikely to disrupt glucose homeostasis under controlled conditions.

Fields of Study & Subjects

Veterinary Pharmacology and Anesthesia Anesthesia and Sedative Agents Veterinary Medicine and Surgery

Publication details

Journal / source
American Journal of Veterinary Research
Volume
87
Issue
7
Publication date
26 March 2026
Language
EN